GPCR/G Protein

Shop By

Items 1-50 of 627

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. PAR-1 Antagonist

    Vorapaxar (SCH 530348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.
  2. NK1 receptor antagonist

    Rolapitant, also known as SCH-619734, is a selective, bioavailable, CNS penetrant neurokinin NK1 receptor antagonist that shows behavioral effects in animals models of emesis.
  3. Smo Antagonist

    LDE225 (NVP-LDE225) is a potent, selective and orally bioavailable Smoothened (SMO) antagonist that inhibits hedgehog (Hh) signaling pathway via antagonism of the Smoothened receptor (SMO).
  4. Orexin Antagonist

    SB-649868 is an orexin receptor antagonist in development by GlaxoSmithKline.
  5. angiotensin AT2 receptor antagonist

    PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. IC50 values are 34 and 210 nM in rat adrenal tissue and brain respectively.
  6. CXCR4 antagonist

    Plerixafor is an immunostimulant used to multiply hematopoietic stem cells and it is a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation.
  7. CXCR4 antagonist

    Plerixafor is an immunostimulant used to multiply hematopoietic stem cells and it is a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation.
  8. 5-HT2A receptor antagonist

    Volinanserin is a highly selective 5-HT2A receptor antagonist.
  9. somatostatin receptor antagonist

    Octreotide is a peptide agonist for sst2, sst3 and sst5 somatostatin receptors. IC50/Kd values (nM) at cloned human somatostatin receptors are: 290 - 1140 (sst1), 0.4 - 2.1 (sst2), 4.4 - 34.5 (sst3), > 1000 (sst4), and 5.6 - 32 (sst5).
  10. OX1 receptor antagonist

    SB 334867 is a selective non-peptide orexin OX1 receptor antagonist. pKb values are 7.2 and < 5 for inhibition of intracellular Ca2+ release in CHO cells expressing human OX1 and OX2 receptors respectively. Blocks orexin-A induced grooming and feeding following systemic administration in vivo.
  11. Histamine H2-receptor antagonist

    Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion.
  12. H2-receptor antagonist

    Cimetidine is a histamine H2-receptor antagonist that inhibits stomach acid production.
  13. α2C antagonist

    JP 1302 2HCl is a potent and selective α2C antagonist.
  14. Histamine Antagonist

    JNJ7777120 is a potent, selective non-imidazole H4?histamine receptor antagonist.
  15. CysLT1 receptor antagonist

    MK-571 is a potent CysLT1 (LTD4) leukotriene receptor inverse agonist with EC50 value of 1.3 nM.
  16. 5-HT1C receptor antagonist

    Clozapine N-oxide is a major metabolite of Clozapine noted to decrease SR-2A (5-HT2 serotonin receptor) density in vitro.
  17. H1 antagonist

    Asenapine shows high affinity (pKi) for numerous receptors, including the serotonin 5-HT1A (8.6), 5-HT1B (8.4), 5-HT2A (10.2), 5-HT2B (9.8), 5-HT2C (10.5), 5-HT5A (8.8), 5-HT6 (9.5), and 5-HT7 (9.9) receptors, the adrenergic α1 (8.9), α2A (8.9), α2B (9.5), and α2C (8.9) receptors, the dopamine D1 (8.9), D2 (8.9), D3 (9.4), and D4 (9.0) receptors, and the histamine H1 (9.0) and H2 (8.2) receptors.
  18. CXCR4 antagonist

    AMD 3465 is a potent, selective CXCR4 antagonist.
  19. orexin receptor antagonist

    Nemorexant (ACT-541468) is a potent orexin receptor antagonist extracted from patent WO2015083094A1, compound example 7, has IC50s of 2 nM and 3 nM for Ox1 receptor and Ox2 receptor, respectively.
  20. Opioid Receptor antagonist

    JTC-801 is a selective antagonist for the nociceptin receptor, also known as the ORL-1 receptor.
  21. bradykinin B1 receptor antagonist

    SSR240612 is a new antagonist of the bradykinin B1 receptor.
  22. Orexin receptor antagonist

    MK6096, also known as filorexant, is an orally bioavailable potent and selective reversible antagonist of OX(1)R and OX(2)R currently in clinical development for insomnia. MK-6096 demonstrated potent binding and antagonism of both human OX(1)R and OX(2)R (<3 nM in binding, 11 nM in FLIPR), with no significant off-target activities against a panel of >170 receptors and enzymes.
  23. somatostatin receptor 2 antagonist

    CYN-154806 is a potent selective somatostatin receptor 2 (sst2) antagonist.
  24. LPA1 receptor antagonist

    AM966 is a high affinity, selective, oral antagonist of LPA1 receptor (lysophosphatidic acid receptor) with an IC50 value of 17 nM.
  25. LPA Receptor Antagonist

    Ki16425 is a LPA receptor antagonist with selectivity for LPA1 and LPA3 and exhibits Ki values of 0.34, 6.5, and 0.93 μM for the human LPA1, LPA2, and LPA3 receptors, respectively.
  26. CGRP Receptor antagonist

    MK 3207 hydrochloride is a potent CGRP receptor antagonist with IC50 of 0.12 nM.
  27. neurokinin-1 receptor antagonist

    Aprepitant is classified as an NK1 antagonist. Aprepitant has been shown to inhibit both the acute and delayed emesis induced by cytotoxic chemotherapeutic drugs by blocking substance P landing on receptors in the brains neurons. It has also been shown to increase the activity of the 5-HT3 receptor antagonists ondansetron and the corticosteroid dexamethasone, which are also used to prevent nausea and vomiting caused by chemotherapy.

  28. β2 adrenergic receptor antagonist

    ICI-118551 is a selective beta2 adrenergic receptor (adrenoreceptor) antagonist.
  29. EndothelinA receptor antagonist

    Ambrisentan functions as an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA).
  30. RAAS antagonist

    Candesartan is an angiotensin receptor blocker (also called an angiotensin-II receptor antagonist or an AIIRA).
  31. 5-HT2C serotonin receptor antagonist

    N-Desmethylclozapine is a potent and selective 5-HT2C serotonin receptor antagonist
  32. A2A antagonist

    Istradefylline (KW-6002) is a selective antagonist at the A2A receptor. It has been found to be useful in the treatment of Parkinson's disease.
  33. 5HT1A antagonist

    WAY-100635 was originally believed to act as a selective 5-HT1A receptor antagonist, but subsequent research showed that it also acts as potent full agonist at the D4 receptor.

  34. H1-receptor antagonist

    Astemizole is a potent antihistamine (H1-receptor antagonist, IC50 = 4 nM) that displays selectivity over dopamine, 5-HT, and muscarinic acetylcholine receptors. This compound has shown potent hERG K+ channel blocking activity (IC50 = 0.9 nM), antimalarial activity in multidrug resistant strains in vitro (IC50 = 227 - 734 nM), and has been used as a chaperone to correct folding defects and restore protein function for some mutated forms of hERG channels.
  35. alpha1/beta adrenergic receptors antagonist

    Labetalol HCl is a dual antagonist for both selective alpha1-adrenergic and nonselective beta-adrenergic receptors.
  36. dopamine D2 receptor antagonist

    Metoclopramide HCl is a selective dopamine D2 receptor antagonist.
  37. Histamine Receptor antagonist

    Bepotastine Beslilate (Bepreve) is a histamine H1 receptor anatagonist.
  38. Dopamine Receptor antagonist

    Paliperidone(Invega) is an atypical antipsychotic.
  39. CXCR1/CXCR2 antagonist

    SCH527123 is a potent and selective antagonist of the human CXCR1 and CXCR2 receptors with IC50 of 42 nM and 3 nM, respectively.
  40. OX1/OX2 Antagonist

    Almorexant HCl is an orally active, dual orexin receptor antagonist with IC50 of 6.6 nM and 3.4 nM for OX1 and OX2 receptor 3.
  41. Adenosine A2A antagonist

    ZM-241385 is a potent and highly selective Adenosine A2A-R antagonist, with a pA2 of 9.02 for Adenosine A2A-R in cardiac vasculature and selectivities of 1000, 91 and 500,000 over Adenosine A1-R, Adenosine A2B-R and Adenosine A3-R sites, respectively.
  42. dopamine D2-receptor antagonist

    Sulpiride is a dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid.
  43. 5-HT2C receptor antagonist

    Puerarin is one of several known isoflavones. Puerarin is a 5-HT2C receptor and benzodiazepine site antagonist. Puerarin is being investigated as a self-microemulsifying drug delivery system.
  44. 5-HT2B receptor antagonist

    RS-127445 is a potent and selective antagonist at the serotonin 5-HT2B receptor, with around 1000x selectivity over the closely related 5-HT2A and 5-HT2C receptors.

  45. S1P Receptor antagonist

    FTY720 is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii as well as a structural analog of sphingosine.
  46. ETA-receptor Antagonist

    Zibotentan (ZD4054)is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).
  47. Dual orexin receptor antagonist

    TCS 1102 is a potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively).
  48. CXCR4 antagonist

    AMD 070 is a CXCR4 chemokine receptor antagonist.
  49. CB2 antagonist

    AM630 is a selectivity CB2 antagonist with Ki of 31.2 nM, > 150 fold selectivity over CB1 receptor.
  50. CB1 receptor antagonist

    AM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors.

Items 1-50 of 627

Page
per page
Set Descending Direction